



Company overview

- Breakthrough platform technology for oral delivery of drugs and vaccines presently available only via injection
- Pipeline currently focused on diabetes, with potential for a variety of additional treatment indications addressing multi-billion-dollar markets
- Positive results from oral insulin (ORMD-0801) pivotal Phase 2b study
- Phase 3 studies under US FDA underway
- Oramed's lead product, oral insulin, has potential to be the first commercial oral insulin
- JV, Oravax Medical (www.ora-vax.com), developing oral Covid-19 vaccine

EQUITY OVERVIEW

(as of 3/18/22)

Nasdaq/TASE: ORMP

Price: ~\$9.74

Market Cap: \$372.88 M

52 Week Range: \$7.52-\$31.54

Avg. Daily Volume (90 day):
766K

Shares Outstanding: 38M
(as of 11/24/21)

Cash/Investments: ~ \$174M
(as of 12/3/21)

ANALYST COVERAGE

- H.C. Wainwright & Co.
- Aegis Capital
- Zack
- AGP
- Canaccord
- Cantor Fitzgerald

UNMET NEED IN DIABETES

- **1 in 10 adults** has diabetes
- **10% of U.S. Healthcare dollars** is spent on diabetes
- **Every 5 seconds** 1 adult dies from diabetes

INVESTMENT HIGHLIGHTS

Breakthrough Platform Technology Delivers Injectable Drugs Orally

Oramed's unique Protein Oral Delivery (POD™) technology enables small proteins such as insulin to travel through the gastrointestinal tract and into the bloodstream. This method is more natural and should eliminate many of the negative side-effects of injection delivery. The oral administration of current injection-only therapies for conditions including diabetes should offer clear benefits including increased compliance and safety, fewer side effects and greater comfort for patients.

Addressing \$483 Billion Market with Oral Formulations

Roughly \$483 billion worth of drugs and vaccines are currently delivered via injection. This includes the diabetes market where \$34.8 billion of insulin and \$11.3 billion of GLP-1 analogs were sold globally in 2019. The vaccine market size was approximately \$61 billion in 2021 and is expected to surpass \$125 billion by 2028.

Oral Treatment has the Potential to Curb Progression of Type 2 Diabetes

ORMD-0801 has the potential to create a new paradigm in the treatment of type 2 diabetes by orally delivering insulin at an earlier stage of treatment. Earlier treatment can potentially slow disease progression and delay late-stage complications. Oramed successfully completed a 90-day HbA1c study of ORMD-0801, which met its primary endpoint achieving a statistically significant reduction of HbA1c. Oramed has initiated Phase 3 studies under the FDA and is pursuing a Biologics License Application (BLA) regulatory pathway for ORMD-0801 which would grant a full 12 years of marketing exclusivity, if approved.

Oral Covid-19 Vaccine in Development

Oravax Medical, based on Oramed's and Premas Biotech's cutting-edge technology is developing an oral Covid-19 vaccine. Oravax's COVID-19 oral vaccine candidate benefits from being a virus like particle (VLP) triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus.

2022 ANTICIPATED MILESTONES

ORMD-0801: Oral Insulin	<ul style="list-style-type: none"> • Phase 3 trial in diabetes patients • NASH Phase 2 trial
ORMD-0901: Oral GLP-1	<ul style="list-style-type: none"> • Bioavailability study in diabetes patients
Oravax Medical	<ul style="list-style-type: none"> • Phase 1 trial for oral Covid-19 vaccine

Disclaimer: Except for historical information contained herein, the statements in this fact sheet are "forward-looking" within the meaning of the Private Securities Litigation Act of 1995. A fuller discussion of Oramed Pharmaceuticals Inc.'s risks and uncertainties are described in the Company's filings with the Securities and Exchange Commission, which should be reviewed in conjunction with this overview

